cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' – NBC Los Angeles Novo Nordisk: Can CagriSema Show

By modulating inflammatory responses, GLP-1RAs can help prevent the degeneration of dopamine-producing cells.413 GLP-1RAs play a neuroprotective role in neurons by facilitating neuronal survival and promoting neuronal growth, thereby preserving the structural and functional integrity of synapses.6,14 Furthermore, GLP-1 signaling indirectly enhances and restores the insulin signaling pathway in neurons, leading to a reduction in the phosphorylation of insulin receptor substrates and the burden caused by monomeric -synuclein.414 Together, these effects contribute to the protection of dopaminergic neurons (source)

Would buy again

Nanomedicines against mitochondrial dysfunction-induced metabolic diseases

High-fat, high-calorie foods that previously seemed irresistible often lose their appeal

GLP-1s in particular they're very potent, you know, a low daily dosing is sufficient for therapeutic effect, and they're reasonably stable, so it kind of lends itself well for incorporation into our implant, Mendelsohn said

1986 Feb;18:S74-9